Recent Advancements in the Prevention and Treatment of Genetic and Non-Genetic Obesity: A Pharmacological Perspective of Review
Abstract
Obesity is a complicated, long-term condition caused by a combination of behavioural, environmental, genetic, and epigenetic factors. It is a significant risk factor for a number of metabolic conditions, such as cardiovascular disease, type 2 diabetes, and some types of cancer. New knowledge and treatment options for obesity prevention and treatment, especially in relation to its hereditary and non-genetic variants, have been made possible by recent developments in pharmacological research. Monogenic, syndromic, and polygenic forms of genetic obesity are frequently caused by mutations or polymorphisms that impact energy expenditure, appetite control, or fat storage processes. Novel pharmacotherapies have focused on important targets such proopiomelanocortin (POMC) neurons, the leptin signalling pathway, and the melanocortin-4 receptor (MC4R). Rare hereditary types of obesity may be treated with medications like setmelanotide, a selective MC4R agonist. Excessive calorie intake, physical inactivity, and psychological problems contribute to non-genetic (or lifestyle-related) obesity, which is still more common and is frequently treated with a mix of medication and lifestyle changes. Clinical trials have shown that recently licensed medications like tirzepatide and semaglutide, which work on the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) pathways, significantly improve metabolism and reduce body weight. The goal of this review is to present a thorough examination of the most recent pharmacological approaches to treating both hereditary and non-genetic obesity. It emphasizes how crucial combination therapy, new drug targets, and precision medicine will be in determining how obesity is treated and prevented in the future.
Keywords: Lipid disorder, genetic obesity, non-genetic obesity, type 2 diabetes, setmelanotide, glucagon-like peptide-1
Keywords:
Lipid disorder, genetic obesity, non-genetic obesity, type 2 diabetes, setmelanotide, glucagon-like peptide-1DOI
https://doi.org/10.22270/jddt.v15i7.7294References
1. Manna P, Jain SK. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metabolic syndrome and related disorders. 2015 Dec 1;13(10):423-44. https://doi.org/10.1089/met.2015.0095
2. Caughey GE, Vitry AI, Gilbert AL, Roughead EE. Prevalence of comorbidity of chronic diseases in Australia. BMC public health. 2008 Dec;8:1-3. https://doi.org/10.1186/1471-2458-8-221
3. Bluher M. Obesity: global epidemiology and pathogenesis. Nature reviews endocrinology. 2019 May; 15(5):288-98. https://doi.org/10.1038/s41574-019-0176-8
4. McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M, Benca RM, Biggio J, Boggiano MM, Eisenmann JC, Elobeid M. Ten putative contributors to the obesity epidemic. Critical reviews in food science and nutrition. 2009 Dec 10;49(10):868-913. https://doi.org/10.1080/10408390903372599
5. Hinney A, Vogel CI, Hebebrand J. From monogenic to polygenic obesity: recent advances. European child & adolescent psychiatry. 2010 Mar;19: 297-310. https://doi.org/10.1007/s00787-010-0096-6
6. Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation. 2016 Jan 12;133(2):187-225 https://doi.org/10.1161/CIRCULATIONAHA.115.018585
7. Sallis JF, Glanz K. The role of built environments in physical activity, eating, and obesity in childhood. The future of children. 2006 Apr 1:89-108. https://doi.org/10.1353/foc.2006.0009
8. Cummings DE. Ghrelin and the short-and long-term regulation of appetite and body weight. Physiology &behavior. 2006 Aug 30;89(1):71-84. https://doi.org/10.1016/j.physbeh.2006.05.022
9. Burnatowska E, Wikarek A, Oboza P, Ogarek N, Glinianowicz M, Kocelak P, Olszanecka-Glinianowicz M. Emotional eating and binge eating disorders and night eating syndrome in polycystic ovary syndrome-a vicious circle of disease: a systematic review. Nutrients. 2023 Jan 6;15(2):295. https://doi.org/10.3390/nu15020295
10. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM: An International Journal of Medicine. 2007 Jul 1;100(7):395-404. https://doi.org/10.1093/qjmed/hcm044
11. Arch JR, Stock MJ, Trayhurn P. Leptin resistance in obese humans: does it exist and what does it mean?. International Journal of Obesity. 1998 Dec;22(12):1159-63. https://doi.org/10.1038/sj.ijo.0800779
12. Bereda G. Pathophysiology and management of dyslipidaemia. Biomed J Sci & Tech Res. 2022;43(2). https://doi.org/10.26717/BJSTR.2022.43.006857
13. Lopes MF. Obesity and related diseases. Gastric Bypass: Bariatric and Metabolic Surgery Perspectives. 2020:31-40. https://doi.org/10.1007/978-3-030-28803-7_4
14. Marti A, Moreno-Aliaga MJ, Hebebrand J, Martinez JA. Genes, lifestyles and obesity. International Journal of Obesity. 2004 Nov;28(3):S29-36. https://doi.org/10.1038/sj.ijo.0802808
15. Farooqi S, O'RAHILLY ST. Genetic syndromes associated with obesity. Endocrinology Adult and Pediatric: Diabetes Mellitus and Obesity E-Book. 2013 Jul 15:25.
16. Maughan B, Kim-Cohen J. Continuities between childhood and adult life. The British Journal of Psychiatry. 2005 Oct;187(4):301-3. https://doi.org/10.1192/bjp.187.4.301
17. Corica D, Aversa T, Valenzise M, Messina MF, Alibrandi A, De Luca F, Wasniewska M. Does family history of obesity, cardiovascular, and metabolic diseases influence onset and severity of childhood obesity?. Frontiers in endocrinology. 2018 May 2;9:187. https://doi.org/10.3389/fendo.2018.00187
18. Beck-Nielsen H, Vaag A, Poulsen P, Gaster M. Metabolic and genetic influence on glucose metabolism in type 2 diabetic subjects-experiences from relatives and twin studies. Best Practice & Research Clinical Endocrinology & Metabolism. 2003 Sep 1;17(3):445-67. https://doi.org/10.1016/S1521-690X(03)00041-1
19. Miller WC. How effective are traditional dietary and exercise interventions for weight loss?. Medicine and science in sports and exercise. 1999 Aug 1;31:1129-34. https://doi.org/10.1097/00005768-199908000-00008
20. Minich DM, Bland JS. Personalized lifestyle medicine: relevance for nutrition and lifestyle recommendations. The Scientific World Journal. 2013;2013(1):129841. https://doi.org/10.1155/2013/129841
21. Mayer J. Genetic, traumatic and environmental factors in the etiology of obesity. Physiological Reviews. 1953 Oct 1;33(4):472-508. https://doi.org/10.1152/physrev.1953.33.4.472
22. Keuroghlian AS, Frankenburg FR, Zanarini MC. The relationship of chronic medical illnesses, poor health-related lifestyle choices, and health care utilization to recovery status in borderline patients over a decade of prospective follow-up. Journal of psychiatric research. 2013 Oct 1;47(10):1499-506. https://doi.org/10.1016/j.jpsychires.2013.06.012
23. Piper NB, Whitfield EA, Stewart GD, Xu X, Furness SG. Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors. Biochemical Pharmacology. 2022 Aug 1;202:115115. https://doi.org/10.1016/j.bcp.2022.115115
24. Stütz AM, Morrison CD, Argyropoulos G. The Agouti-related protein and its role in energy homeostasis. Peptides. 2005 Oct 1;26(10):1771-81. https://doi.org/10.1016/j.peptides.2004.12.024
25. Krashes MJ, Lowell BB, Garfield AS. Melanocortin-4 receptor-regulated energy homeostasis. Nature neuroscience. 2016 Feb;19(2):206-19. https://doi.org/10.1038/nn.4202
26. Jequier E. Leptin signaling, adiposity, and energy balance. Annals of the New York Academy of Sciences. 2002 Jun;967(1):379-88. https://doi.org/10.1111/j.1749-6632.2002.tb04293.x
27. Friedman JM. Leptin and the endocrine control of energy balance. Nature metabolism. 2019 Aug;1(8):754-64. https://doi.org/10.1038/s42255-019-0095-y
28. Zhang F, Chen Y, Heiman M, DiMarchi R. Leptin: structure, function and biology. Vitamins & hormones. 2005 Jan 1;71:345-72. https://doi.org/10.1016/S0083-6729(05)71012-8
29. Mullen M, Gonzalez-Perez RR. Leptin-induced JAK/STAT signaling and cancer growth. Vaccines. 2016 Jul 26;4(3):26. https://doi.org/10.3390/vaccines4030026
30. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. Journal of the American College of Cardiology. 2008 Oct 7;52(15):1201-10. https://doi.org/10.1016/j.jacc.2008.05.060
31. Cassidy SB, Driscoll DJ. Prader-willi syndrome. European journal of human genetics. 2009 Jan;17(1):3-13. https://doi.org/10.1038/ejhg.2008.165
32. Nicholls RD, Knepper JL. Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annual review of genomics and human genetics. 2001 Sep;2(1):153-75. https://doi.org/10.1146/annurev.genom.2.1.153
33. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, Aerts J, Andrews TD, Barnes C, Campbell P, Fitzgerald T. Origins and functional impact of copy number variation in the human genome. Nature. 2010 Apr 1;464(7289):704-12. https://doi.org/10.1038/nature08516
34. Müller HL, Tauber M, Lawson EA, Özyurt J, Bison B, Martinez-Barbera JP, Puget S, Merchant TE, van Santen HM. Hypothalamic syndrome. Nature reviews Disease primers. 2022 Apr 21;8(1):24. https://doi.org/10.1038/s41572-022-00351-z
35. Arora S. Role of neuropeptides in appetite regulation and obesity-a review. Neuropeptides. 2006 Dec 1;40(6):375-401. https://doi.org/10.1016/j.npep.2006.07.001
36. Guo DF, Rahmouni K. Molecular basis of the obesity associated with Bardet-Biedl syndrome. Trends in Endocrinology & Metabolism. 2011 Jul 1;22(7):286-93. https://doi.org/10.1016/j.tem.2011.02.009
37. Anvarian Z, Mykytyn K, Mukhopadhyay S, Pedersen LB, Christensen ST. Cellular signalling by primary cilia in development, organ function and disease. Nature Reviews Nephrology. 2019 Apr;15(4):199-219. https://doi.org/10.1038/s41581-019-0116-9
38. Simms M. Intellectual and developmental disability. Nelson Pediatric Symptom-Based Diagnosis E-Book. 2017 Mar 8;366.
39. Badano JL, Mitsuma N, Beales PL, Katsanis N. The ciliopathies: an emerging class of human genetic disorders. Annu. Rev. Genomics Hum. Genet.. 2006 Sep 22;7(1):125-48. https://doi.org/10.1146/annurev.genom.7.080505.115610
40. Winnicott DW, Nussbaum M. The family and individual development. Routledge; 2012 Dec 6. https://doi.org/10.4324/9780203440933
41. Speakman JR. The 'fat mass and obesity related'(FTO) gene: mechanisms of impact on obesity and energy balance. Current obesity reports. 2015 Mar;4(1):73-91. https://doi.org/10.1007/s13679-015-0143-1
42. Fawcett KA, Barroso I. The genetics of obesity: FTO leads the way. Trends in genetics. 2010 Jun 1;26(6):266-74. https://doi.org/10.1016/j.tig.2010.02.006
43. Fredriksson R, Hägglund M, Olszewski PK, Stephansson O, Jacobsson JA, Olszewska AM, Levine AS, Lindblom J, Schiöth HB. The obesity gene, FTO, is of ancient origin, up-regulated during food deprivation and expressed in neurons of feeding-related nuclei of the brain. Endocrinology. 2008 May 1;149(5):2062-71. https://doi.org/10.1210/en.2007-1457
44. Redfield AC. The biological control of chemical factors in the environment. American scientist. 1958 Sep 1;46(3):230A-21.
45. Pierzynski GM, Vance GF, Sims JT. Soils and environmental quality. CRC press; 2005 May 2. https://doi.org/10.1201/b12786
46. Altieri MA. Agroecology: the science of sustainable agriculture. CrC press; 2018 Feb 19. https://doi.org/10.1201/9780429495465
47. Folke C. Resilience: The emergence of a perspective for social-ecological systems analyses. Global environmental change. 2006 Aug 1;16(3):253-67. https://doi.org/10.1016/j.gloenvcha.2006.04.002
48. Walsh R. Lifestyle and mental health. American psychologist. 2011 Oct;66(7):579. https://doi.org/10.1037/a0021769
49. Gambles R, Lewis S, Rapoport R. The myth of work-life balance: The challenge of our time for men, women and societies. John Wiley & Sons; 2006 Feb 22. https://doi.org/10.1002/9780470713266
50. Carson JW, Carson KM, Gil KM, Baucom DH. Mindfulness-based relationship enhancement. Behavior therapy. 2004 Jun 1;35(3):471-94. https://doi.org/10.1016/S0005-7894(04)80028-5
51. Scott D, Happell B. The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness. Issues in mental health nursing. 2011 Aug 19;32(9):589-97. https://doi.org/10.3109/01612840.2011.569846
52. Nussbaum M, Sen A, editors. The quality of life. Clarendon press; 1993 Mar 11. https://doi.org/10.1093/0198287976.001.0001
53. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC. Heart failure: preventing disease and death worldwide. ESC heart failure. 2014 Sep;1(1):4-25. https://doi.org/10.1002/ehf2.12005
54. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. Jama. 2008 Dec 24;300(24):2867-78. https://doi.org/10.1001/jama.2008.892
55. Chapman CR, Tuckett RP, Song CW. Pain and stress in a systems perspective: reciprocal neural, endocrine, and immune interactions. The Journal of Pain. 2008 Feb 1;9(2):122-45. https://doi.org/10.1016/j.jpain.2007.09.006
56. Newson AJ. Ethical aspects arising from non-invasive fetal diagnosis. InSeminars in Fetal and Neonatal Medicine 2008 Apr 1 (Vol. 13, No. 2, pp. 103-108). WB Saunders. https://doi.org/10.1016/j.siny.2007.12.004
57. Kehlet H, Wilmore DW. Multimodal strategies to improve surgical outcome. The American journal of surgery. 2002 Jun 1;183(6):630-41. https://doi.org/10.1016/S0002-9610(02)00866-8
58. McLellan AT, Lewis DC, O'brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. Jama. 2000 Oct 4;284(13):1689-95. https://doi.org/10.1001/jama.284.13.1689
59. Consensus Conference Panel:, Watson NF, Badr MS, Belenky G, Bliwise DL, Buxton OM, Buysse D, Dinges DF, Gangwisch J, Grandner MA, Kushida C. Joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society on the recommended amount of sleep for a healthy adult: methodology and discussion. Journal of Clinical Sleep Medicine. 2015 Aug 15;11(8):931-52. https://doi.org/10.5664/jcsm.4950
60. Schacter DL. The seven sins of memory: insights from psychology and cognitive neuroscience. American psychologist. 1999 Mar;54(3):182. https://doi.org/10.1037//0003-066X.54.3.182
61. Chattu VK, Manzar MD, Kumary S, Burman D, Spence DW, Pandi-Perumal SR. The global problem of insufficient sleep and its serious public health implications. InHealthcare 2018 Dec 20 (Vol. 7, No. 1, p. 1). MDPI. https://doi.org/10.3390/healthcare7010001
62. Del Río JP, Alliende MI, Molina N, Serrano FG, Molina S, Vigil P. Steroid hormones and their action in women's brains: the importance of hormonal balance. Frontiers in public health. 2018 May 23;6:141. https://doi.org/10.3389/fpubh.2018.00141
63. Reilly DM, Lozano J. Skin collagen through the lifestages: Importance for skin health and beauty. Plastic and Aesthetic Research. 2021 Jan 8;8:N-A. https://doi.org/10.20517/2347-9264.2020.153
64. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD. Pharmacological management of obesity: an endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2015 Feb 1;100(2):342-62. https://doi.org/10.1210/jc.2014-3415
65. Farooqi IS, O'rahilly S. Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity. Nature clinical practice Endocrinology & metabolism. 2008 Oct;4(10):569-77. https://doi.org/10.1038/ncpendmet0966
66. Vineis P, Stringhini S, Porta M. The environmental roots of non-communicable diseases (NCDs) and the epigenetic impacts of globalization. Environmental research. 2014 Aug 1;133:424-30. https://doi.org/10.1016/j.envres.2014.02.002
67. Loos RJ, Yeo GS. The genetics of obesity: from discovery to biology. Nature Reviews Genetics. 2022 Feb;23(2):120-33. https://doi.org/10.1038/s41576-021-00414-z
68. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. bmj. 2016 Aug 9;354. https://doi.org/10.1136/bmj.i3857
69. Gelber AC. Knee osteoarthritis. Annals of internal medicine. 2024 Sep;177(9):ITC129-44. https://doi.org/10.7326/ANNALS-24-01249
70. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2000 Mar;20(3):270-9. https://doi.org/10.1592/phco.20.4.270.34882
71. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug safety. 2008 Jan;31:53-65. https://doi.org/10.2165/00002018-200831010-00005
72. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2000 Mar;20(3):270-9. https://doi.org/10.1592/phco.20.4.270.34882
73. Coulter AA, Rebello CJ, Greenway FL. Centrally acting agents for obesity: past, present, and future. Drugs. 2018 Jul;78:1113-32. https://doi.org/10.1007/s40265-018-0946-y
74. Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert review of cardiovascular therapy. 2010 Dec 1;8(12):1777-801. https://doi.org/10.1586/erc.10.125
75. Gustafson A, King C, Rey JA. Lorcaserin (Belviq): a selective serotonin 5-HT2C agonist in the treatment of obesity. Pharmacy and Therapeutics. 2013 Sep;38(9):525.
76. Procyshyn RM, Halpape K, Kim DD, editors. Clinical handbook of psychotropic drugs. Hogrefe Publishing; 2025 May 12. https://doi.org/10.1027/00668-000
77. DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016 Feb 1;65(2):20-9. https://doi.org/10.1016/j.metabol.2015.10.014
78. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. Jama. 1998 Jun 24;279(24):1977-83. https://doi.org/10.1001/jama.279.24.1977
79. Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, De Sarro G, Gallelli L. Pharmacokinetic drug-drug interaction and their implication in clinical management. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2013 Jul;18(7):601.
80. Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease. Drug design, development and therapy. 2016 Oct 3:3267-79. https://doi.org/10.2147/DDDT.S86463
81. Daughton CG, Ruhoy IS. Green pharmacy and pharmEcovigilance: prescribing and the planet. Expert review of clinical pharmacology. 2011 Mar 1;4(2):211-32. https://doi.org/10.1586/ecp.11.6
82. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. European journal of pharmacology. 2018 Sep 5;834:188-96. https://doi.org/10.1016/j.ejphar.2018.07.034
83. Obodozie OO. Pharmacokinetics and drug interactions of herbal medicines: A missing critical step in the phytomedicine/drug development process. Reading in Advanced Pharmacokinetics-Theory, Methods, and Applications. Croatia: InTech. 2012 Apr 20:127-56.
84. Guengerich FP. Cytochrome p450 and chemical toxicology. Chemical research in toxicology. 2008 Jan 21;21(1):70-83. https://doi.org/10.1021/tx700079z
85. Kaneko JJ. Carbohydrate metabolism and its diseases. InClinical biochemistry of domestic animals 1997 Jan 1 (pp. 45-81). Academic Press. https://doi.org/10.1016/B978-012396305-5/50004-X
86. Strickland M, Stoll EA. Metabolic reprogramming in glioma. Frontiers in cell and developmental biology. 2017 Apr 26;5:43. https://doi.org/10.3389/fcell.2017.00043
87. Maughan RJ, Gleeson M. The biochemical basis of sports performance. Oxford University Press; 2010 May 20. https://doi.org/10.1093/hesc/9780199208289.001.0001
88. Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nature reviews Drug discovery. 2009 Feb;8(2):111-28. https://doi.org/10.1038/nrd2683
89. Hayes AW, Kobets T. Hayes' principles and methods of toxicology. Crc Press; 2023 Jul 3. https://doi.org/10.1201/9781003390008
90. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer research. 2010 Jan 15;70(2):440-6. https://doi.org/10.1158/0008-5472.CAN-09-1947
91. van Boekel M, Fogliano V, Pellegrini N, Stanton C, Scholz G, Lalljie S, Somoza V, Knorr D, Jasti PR, Eisenbrand G. A review on the beneficial aspects of food processing. Molecular nutrition & food research. 2010 Sep;54(9):1215-47. https://doi.org/10.1002/mnfr.200900608
92. Benet LZ, Kroetz D, Sheiner L, Hardman J, Limbird L. Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination. Goodman and Gilman's the pharmacological basis of therapeutics. 1996;3:e27.
93. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacological reviews. 1997 Dec 1;49(4):403-49. https://doi.org/10.1016/S0031-6997(24)01340-1
94. De Sire A, Ferrillo M, Lippi L, Agostini F, de Sire R, Ferrara PE, Raguso G, Riso S, Roccuzzo A, Ronconi G, Invernizzi M. Sarcopenic dysphagia, malnutrition, and oral frailty in elderly: a comprehensive review. Nutrients. 2022 Feb 25;14(5):982. https://doi.org/10.3390/nu14050982
95. Street Jr RL, Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician-patient communication to health outcomes. Patient education and counseling. 2009 Mar 1;74(3):295-301. https://doi.org/10.1016/j.pec.2008.11.015
96. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation. 1999 Apr 27;99(16):2192-217. https://doi.org/10.1161/01.CIR.99.16.2192
97. Snyderman R. Personalized health care: from theory to practice. Biotechnology journal. 2012 Aug;7(8):973-9. https://doi.org/10.1002/biot.201100297
98. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2000 Mar;20(3):270-9. https://doi.org/10.1592/phco.20.4.270.34882
99. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs in context. 2015 Jul 9;4:212283. https://doi.org/10.7573/dic.212283
100. Haddad F, Dokmak G, Bader M, Karaman R. A comprehensive review on weight loss associated with anti-diabetic medications. Life. 2023 Apr 14;13(4):1012 https://doi.org/10.3390/life13041012
101. Kshatriya D, Bello NT. Central Nervous System Stimulants and Drugs That Suppress Appetite. InSide Effects of Drugs Annual 2018 Jan 1 (Vol. 40, pp. 1-9). Elsevier. https://doi.org/10.1016/bs.seda.2018.08.014
102. Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, St Jeor S. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert opinion on pharmacotherapy. 2009 Apr 1;10(6):1069-81. https://doi.org/10.1517/14656560902775750
103. Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Current drug abuse reviews. 2009 May 1;2(2):135-42. https://doi.org/10.2174/1874473710902020135
104. Welling PG. Influence of food and diet on gastrointestinal drug absorption: a review. Journal of Pharmacokinetics and Biopharmaceutics. 1977 Aug;5:291-334. https://doi.org/10.1007/BF01061694
105. Clarke JR, Ribeiro FC, Frozza RL, De Felice FG, Lourenco MV. Metabolic dysfunction in Alzheimer's disease: from basic neurobiology to clinical approaches. Journal of Alzheimer's Disease. 2018 Jun 12;64(s1):S405-26. https://doi.org/10.3233/JAD-179911
106. Romoli M, Mazzocchetti P, D'Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, Calabresi P, Costa C. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Current neuropharmacology. 2019 Oct 1;17(10):926-46. https://doi.org/10.2174/1570159X17666181227165722
107. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circulation research. 2004 May 14;94(9):1168-78. https://doi.org/10.1161/01.RES.0000127122.22685.0A
108. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clinical Pharmacology & Therapeutics. 2014 Jan;95(1):53-66. https://doi.org/10.1038/clpt.2013.204
109. Lafferty RA, Flatt PR, Irwin N. Is polypharmacy the future for pharmacological management of obesity?. Current Opinion in Endocrine and Metabolic Research. 2022 Apr 1;23:100322. https://doi.org/10.1016/j.coemr.2022.100322
110. Jerlhag E, Egecioglu E, Dickson SL, Douhan A, Svensson L, Engel JA. Preclinical study: ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addiction biology. 2007 Mar;12(1):6-16. https://doi.org/10.1111/j.1369-1600.2006.00041.x
111. Bartelt A, Heeren J. Adipose tissue browning and metabolic health. Nature Reviews Endocrinology. 2014 Jan;10(1):24-36. Marcos P, Coveñas R. Involvement of the orexinergic system in feeding. Applied Sciences. 2021 Dec 22;12(1):86. https://doi.org/10.1038/nrendo.2013.204
112. Marcos P, Coveñas R. Involvement of the orexinergic system in feeding. Applied Sciences. 2021 Dec 22;12(1):86. https://doi.org/10.3390/app12010086
113. Ahrén B. The future of incretin‐based therapy: novel avenues-novel targets. Diabetes, Obesity and Metabolism. 2011 Oct;13:158-66. https://doi.org/10.1111/j.1463-1326.2011.01457.x
114. Sorensen HT. Use of medical databases in clinical epidemiology. Christensen T, Schlosser HK, Pedersen L, editors. Aarhus, Denmark: Department of Clinical Epidemiology, Aarhus University Hospital; 2009.
115. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. Journal of the American College of Nutrition. 2007 Aug 1;26(4):373S-88S. https://doi.org/10.1080/07315724.2007.10719626
116. Semwal RB, Semwal DK, Vermaak I, Viljoen A. A comprehensive scientific overview of Garcinia cambogia. Fitoterapia. 2015 Apr 1;102:134-48. https://doi.org/10.1016/j.fitote.2015.02.012
117. Freedman MR, King J, Kennedy E. Popular diets: a scientific review.
118. Govindarajan VS, Sathyanarayana MN. Capsicum-production, technology, chemistry, and quality. Part V. Impact on physiology, pharmacology, nutrition, and metabolism; structure, pungency, pain, and desensitization sequences. Critical Reviews in Food Science & Nutrition. 1991 Jan 1;29(6):435-74. https://doi.org/10.1080/10408399109527536
119. Henderson S, Magu B, Rasmussen C, Lancaster S, Kerksick C, Smith P, Melton C, Cowan P, Greenwood M, Earnest C, Almada A. Effects of coleus forskohlii supplementation on body composition and hematological profiles in mildly overweight women. Journal of the International Society of Sports Nutrition. 2005 Dec;2:1-9. https://doi.org/10.1186/1550-2783-2-2-54
120. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006 Aug 1;55(8):2256-64. https://doi.org/10.2337/db06-0006
121. Houston M. WHAT YOUR DOCTOR MAY NOT TELL YOU ABOUT (TM): HEART DISEASE. Grand Central Life & Style; 2012 Feb 6.
122. Tierra M. The way of herbs. Simon and Schuster; 1998 Aug 1.
123. Van Heerden FR. Hoodia gordonii: a natural appetite suppressant. Journal of Ethnopharmacology. 2008 Oct 28;119(3):434-7. https://doi.org/10.1016/j.jep.2008.08.023
124. Choudhary D, Bhattacharyya S, Joshi K. Body weight management in adults under chronic stress through treatment with ashwagandha root extract: a double-blind, randomized, placebo-controlled trial. Journal of evidence-based complementary & alternative medicine. 2017 Jan;22(1):96-106. https://doi.org/10.1177/2156587216641830
125. Tierra M. The way of herbs. Simon and Schuster; 1998 Aug 1.
126. Muzzarelli RA. Chitosan-based dietary foods. Carbohydrate Polymers. 1996 Apr 1;29(4):309-16 https://doi.org/10.1016/S0144-8617(96)00033-1
127. Cold CJ, Taylor JR. The prepuce. BJU international. 1999 Jan;83(S1):34-44. https://doi.org/10.1046/j.1464-410x.1999.0830s1034.x
128. Jikah AN, Edo GI. Moringa oleifera: a valuable insight into recent advances in medicinal uses and pharmacological activities. Journal of the Science of Food and Agriculture. 2023 Dec;103(15):7343-61. https://doi.org/10.1002/jsfa.12892
129. Murray MT, Pizzorno J. The encyclopedia of healing foods. Simon and Schuster; 2010 May 11.
130. 130. Bode AM, Dong Z. The amazing and mighty ginger. Herbal medicine: Biomolecular and clinical aspects. 2011 Mar 28;2.
131. Brewer MS. Natural antioxidants: sources, compounds, mechanisms of action, and potential applications. Comprehensive reviews in food science and food safety. 2011 Jul;10(4):221-47. https://doi.org/10.1111/j.1541-4337.2011.00156.x
132. Juneja LR, Chu DC, Okubo T, Nagato Y, Yokogoshi H. L-theanine-a unique amino acid of green tea and its relaxation effect in humans. Trends in Food Science & Technology. 1999 Jun 1;10(6-7):199-204. https://doi.org/10.1016/S0924-2244(99)00044-8
133. Heiss ML, Heiss RJ. The tea enthusiast's handbook: a guide to the world's best teas. Ten Speed Press; 2012 Jan 18.
134. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochemical pharmacology. 2011 Dec 15;82(12):1807-21. https://doi.org/10.1016/j.bcp.2011.07.093
135. Kim HS, Quon MJ, Kim JA. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox biology. 2014 Jan 1;2:187-95. https://doi.org/10.1016/j.redox.2013.12.022
136. Stahl SM, Stahl SM. Essential psychopharmacology: Neuroscientific basis and practical applications. Cambridge university press; 2000 Jul 13.
137. Tsai AG, Wadden TA. Systematic review: an evaluation of major commercial weight loss programs in the United States. Annals of internal medicine. 2005 Jan 4;142(1):56-66. https://doi.org/10.7326/0003-4819-142-1-200501040-00012
138. Semwal RB, Semwal DK, Vermaak I, Viljoen A. A comprehensive scientific overview of Garcinia cambogia. Fitoterapia. 2015 Apr 1;102:134-48. https://doi.org/10.1016/j.fitote.2015.02.012
139. Jena BS, Jayaprakasha GK, Singh RP, Sakariah KK. Chemistry and biochemistry of (−)-hydroxycitric acid from Garcinia. Journal of agricultural and food chemistry. 2002 Jan 2;50(1):10-22. https://doi.org/10.1021/jf010753k
140. Chuah LO, Yeap SK, Ho WY, Beh BK, Alitheen NB. In vitro and in vivo toxicity of garcinia or hydroxycitric acid: a review. Evidence‐Based Complementary and Alternative Medicine. 2012;2012(1):197920. https://doi.org/10.1155/2012/197920
141. Chua M, Baldwin TC, Hocking TJ, Chan K. Traditional uses and potential health benefits of Amorphophallus konjac K. Koch ex NE Br. Journal of ethnopharmacology. 2010 Mar 24;128(2):268-78. https://doi.org/10.1016/j.jep.2010.01.021
142. Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation. 2016 Jan 12;133(2):187-225. https://doi.org/10.1161/CIRCULATIONAHA.115.018585
143. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Frontiers in pharmacology. 2014 Jan 10;4:177. https://doi.org/10.3389/fphar.2013.00177
144. Guo L, Yokoyama W, Chen M, Zhong F. Konjac glucomannan molecular and rheological properties that delay gastric emptying and improve the regulation of appetite. Food Hydrocolloids. 2021 Nov 1;120:106894. https://doi.org/10.1016/j.foodhyd.2021.106894
145. Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP. Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Annals of internal medicine. 2005 Mar 15;142(6):403-11. https://doi.org/10.7326/0003-4819-142-6-200503150-00006
146. Srinivasan K. Biological activities of red pepper (Capsicum annuum) and its pungent principle capsaicin: a review. Critical reviews in food science and nutrition. 2016 Jul 3;56(9):1488-500. https://doi.org/10.1080/10408398.2013.772090
147. Frias B, Merighi A. Capsaicin, nociception and pain. Molecules. 2016 Jun 18;21(6):797. https://doi.org/10.3390/molecules21060797
148. Sachan AK, Kumar S, Kumari K, Singh D. Medicinal uses of spices used in our traditional culture: Worldwide. Journal of Medicinal Plants Studies. 2018 Jan 1;6(3):116-22.
149. Farrell KT. Spices, condiments and seasonings. Springer Science & Business Media; 1998 Aug 31.
150. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacological reviews. 1999 Jun 1;51(2):159-211. https://doi.org/10.1016/S0031-6997(24)01403-0
151. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. Journal of Clinical Neurophysiology. 1997 Jan 1;14(1):2-31. https://doi.org/10.1097/00004691-199701000-00002
152. McCarty MF, DiNicolantonio JJ, O'Keefe JH. Capsaicin may have important potential for promoting vascular and metabolic health. Open Heart. 2015 Jun 1;2(1):e000262. https://doi.org/10.1136/openhrt-2015-000262
153. Ding X, Staudinger JL. Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase a signal transduction pathway. The Journal of pharmacology and experimental therapeutics. 2005 Feb 1;312(2):849-56. https://doi.org/10.1124/jpet.104.076331
154. Granic I, Lobel A, Engels RC. The benefits of playing video games. American psychologist. 2014 Jan;69(1):66. https://doi.org/10.1037/a0034857
155. Machado SA, Pasquarelli-do-Nascimento G, Da Silva DS, Farias GR, de Oliveira Santos I, Baptista LB, Magalhães KG. Browning of the white adipose tissue regulation: New insights into nutritional and metabolic relevance in health and diseases. Nutrition & metabolism. 2022 Sep 6;19(1):61. https://doi.org/10.1186/s12986-022-00694-0
156. Seamon KB, Daly JW. Forskolin, cyclic AMP and cellular physiology. Trends in Pharmacological Sciences. 1983 Jan 1;4:120-3. https://doi.org/10.1016/0165-6147(83)90326-7
157. Alasbahi RH, Melzig MF. Forskolin and derivatives as tools for studying the role of cAMP. Die Pharmazie-An International Journal of Pharmaceutical Sciences. 2012 Jan 1;67(1):5-13.
158. . Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. American family physician. 2009 Jan 1;79(1):29-36.
159. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, Kim WS, Kim JB. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. American Journal of Physiology-Endocrinology and Metabolism. 2009 Apr;296(4):E955-64. https://doi.org/10.1152/ajpendo.90599.2008
160. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006 Dec 14;444(7121):860-7. https://doi.org/10.1038/nature05485
161. Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, He CY, Feng R, Ma C, Wen BY, Guo F, Yang XY. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism. 2017 May 1;70:72-84. https://doi.org/10.1016/j.metabol.2017.02.003
162. Kumar N. Introduction to spices, plantation crops, medicinal and aromatic plants. Oxford and IBH Publishing; 1997.
163. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Archives of internal medicine. 1998 Nov 9;158(20):2200-11. https://doi.org/10.1001/archinte.158.20.2200
164. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nature Reviews Immunology. 2015 Feb;15(2):104-16. https://doi.org/10.1038/nri3793
165. Peng Y, Ao M, Dong B, Jiang Y, Yu L, Chen Z, Hu C, Xu R. Anti-inflammatory effects of curcumin in the inflammatory diseases: status, limitations and countermeasures. Drug design, development and therapy. 2021 Nov 2:4503-25. https://doi.org/10.2147/DDDT.S327378
166. Raghavan S. Handbook of spices, seasonings, and flavorings. CRC press; 2006 Oct 23. https://doi.org/10.1201/b13597
167. Kumar S, Narwal S, Kumar V, Prakash O. α-glucosidase inhibitors from plants: A natural approach to treat diabetes. Pharmacognosy reviews. 2011 Jan;5(9):19. https://doi.org/10.4103/0973-7847.79096
168. Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal transduction and targeted therapy. 2022 Jul 6;7(1):216. https://doi.org/10.1038/s41392-022-01073-0
169. Amara AA, Shibl A. Role of Probiotics in health improvement, infection control and disease treatment and management. Saudi pharmaceutical journal. 2015 Apr 1;23(2):107-14. https://doi.org/10.1016/j.jsps.2013.07.001
170. Van Heerden FR. Hoodia gordonii: a natural appetite suppressant. Journal of Ethnopharmacology. 2008 Oct 28;119(3):434-7. https://doi.org/10.1016/j.jep.2008.08.023
171. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery. 2022 Mar;21(3):201-23. https://doi.org/10.1038/s41573-021-00337-8
172. Halford JC, Harrold JA. Satiety-enhancing products for appetite control: science and regulation of functional foods for weight management. Proceedings of the Nutrition Society. 2012 May;71(2):350-62. https://doi.org/10.1017/S0029665112000134
173. Winston D. Adaptogens: herbs for strength, stamina, and stress relief. Simon and Schuster; 2019 Sep 17.
174. Panossian A, Wikman G. Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. Pharmaceuticals. 2010 Jan;3(1):188-224. https://doi.org/10.3390/ph3010188
175. Speers AB, Cabey KA, Soumyanath A, Wright KM. Effects of Withania somnifera (Ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia. Current neuropharmacology. 2021 Sep 1;19(9):1468-95. https://doi.org/10.2174/1570159X19666210712151556
176. Malhotra SK. Fennel and fennel seed. InHandbook of herbs and spices 2012 Jan 1 (pp. 275-302). Woodhead Publishing. https://doi.org/10.1533/9780857095688.275
177. Kurita K. Chitin and chitosan: functional biopolymers from marine crustaceans. Marine biotechnology. 2006 Jun;8:203-26. https://doi.org/10.1007/s10126-005-0097-5
178. . Dixit S, Tripathi A, Kumar P. Medicinal properties of Moringa oleifera: A review. Int J Educ Sci Res Rev. 2016 Apr;3(2):173-85.
179. . Stewart-Wade SM, Neumann S, Collins LL, Boland GJ. The biology of Canadian weeds. 117. Taraxacum officinale GH Weber ex Wiggers. Canadian journal of plant science. 2002 Oct 1;82(4):825-53. https://doi.org/10.4141/P01-010
180. Rodriguez-Leyva D, Bassett CM, McCullough R, Pierce GN. The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Canadian Journal of Cardiology. 2010 Nov 1;26(9):489-96. https://doi.org/10.1016/S0828-282X(10)70455-4
181. Gottschall E. Digestion-gut-autism connection: the specific carbohydrate diet. Medical Veritas. 2004;1(2):261-71. https://doi.org/10.1588/medver.2004.01.00029
182. Annicchiarico P, Barrett B, Brummer EC, Julier B, Marshall AH. Achievements and challenges in improving temperate perennial forage legumes. Critical Reviews in Plant Sciences. 2015 Jun 1;34(1-3):327-80. https://doi.org/10.1080/07352689.2014.898462
183. Shahrajabian MH, Sun W, Cheng Q. Clinical aspects and health benefits of ginger (Zingiber officinale) in both traditional Chinese medicine and modern industry. Acta agriculturae scandinavica, section b-Soil & Plant Science. 2019 Aug 18;69(6):546-56. https://doi.org/10.1080/09064710.2019.1606930
184. Sharma HD, Sharma V. Production technology of ginger under changing climate. Vegetable Production Under Changing Climate Scenario. 2012:44-52
Published
Abstract Display: 616 
PDF Downloads: 640 PDF Downloads: 75 How to Cite
Issue
Section
Copyright (c) 2025 Trilochan Satapathy , Laxmi Sahu , Renuka Verma, Poonam Sahu , Kamaksha Tiwari , Nikita Patel , Pratibha Dhiwar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.